NAGOYA, Japan – Medical and Biological Laboratories Co., Ltd. (MBL), a JSR Life Sciences company, announced today that its subsidiary company, G&G Science Co., Ltd., has successfully completed development of a real-time PCR assay kit for “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The kit was evaluated with clinical samples provided by the National Institute of Infectious Diseases (NIID). NIID and the Japan Ministry of Health, Labour and Welfare (MHLW) today published that the results of testing with the kit corresponded 100 percent to those of the current NIID system on both positive and negative agreement rates. Therefore, starting immediately, the kit can be used not only for emergency testing being executed under the Infectious Diseases Control Law of Japan, but also for the clinical testing for the coverage of public medical insurance.
Sunnyvale, CA – June 18, 2019 – JSR Life Sciences, LLC announced today that Tim Lowery has assumed the role of president where he will oversee the Company’s global operations, which include JSR affiliate companies Crown Bioscience, KBI Biopharma, Inc., Medical & Biological Laboratories Co., LTD., Selexis SA and other affiliates throughout Europe and the Asia-Pacific region.
Join our April 5 webinar where Ping Huang, Director, Head of DS BioProcesses, OED, Abbvie at Redwood and Masayoshi Nagaya, Sr. Global Technology Manager at JSR Life Sciences will introduce Chromassette® and an application example of an integrated rapid single pass process from harvest to purified bulk, a concept demonstrated by AbbVie.
Tokyo – Nov. 21, 2017 – JSR Corporation announced today that it held the opening ceremony of the JSR-Keio University Medical and Chemical Innovation Center (JKiC) on October 28 at the Keio University Shinanomachi Campus.
On Wednesday September 13th, our colleague Gerald Platteau gave a presentation about the purification of antibody fragments with Amsphere™ A3 protein A resin.
JSR Corporation (JSR) announced that it has agreed to acquire Lexi Co., Ltd. (Lexi) a medical 3D software company. Through this acquisition, JSR will establish a new business in life sciences by integrating Lexi's 3D software technology with JSR's 3D printing and materials technologies. The JSR Group is focused on creating novel value and capitalizing on the trend toward digitization in the medical and life sciences industries.
JSR Life Sciences, the life-sciences focused division of JSR Corporation, will offer industry partners best-in-class CDMO services by complementing its commercial subsidiary KBI Biopharma with Selexis SA Technologies